Trevi Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In New Havenconnecticutthe Company Focuses On Developing And Commercializing Its Investigational Therapyhaduviowhich Is An Oral Formulation Of Nalbuphine Extended Releasehaduvio Is Designed To Treat Serious Cough Conditionsspecifically Chronic Cough In Patients With Idiopathic Pulmonary Fibrosisipfand Refractory Chronic Coughrcchaduvio Operates As A Kappa Agonist And Mu Antagonisttargeting Opioid Receptors To Manage Cough Hypersensitivityit Is The First Therapy In Clinical Development To Demonstrate A Statistically Significant Reduction In Chronic Cough For Patients With Both Ipf And Rcctrevi Therapeutics Aims To Address Unmet Medical Needs In These Areaspositioning Itself As A Leader In The Treatment Of Chronic Coughthe Company Is Publicly Traded On The Nasdaq Under The Ticker Symbol Trvi
Bio International Convention 2025
United States
16 Jun 2025
635
| Company Name | Trevi Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
